TSBX insider filings

Turnstone Biologics Corp. — 25 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-08-12. Screen TSBX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for TSBX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Turnstone Biologics Corp.

FiledFormInsiderReported transactionsSource
2025-08-124Versant Ventures V, LLC — 10% owner
Versant Venture Capital V, L.P. — 10% owner
Versant Ophthalmic Affiliates I, L.P. — 10% owner
Versant Affiliates Fund V, L.P. — 10% owner
Versant Ventures V GP-GP (Canada), Inc. — 10% owner
Versant Ventures V (Canada), L.P. — 10% owner
Versant Venture Capital V (Canada), LP — 10% owner
Versant Vantage II GP-GP, LLC — 10% owner
Versant Vantage II GP, L.P. — 10% owner
Versant Vantage II, L.P. — 10% owner
Code (U): 2,726,322 · Code (U): 207,486 · Code (U): 90,888 · Code (U): 82,006 · Code (U): 274,990EDGAR
2025-08-124ORBIMED ADVISORS LLC — Director
OrbiMed Capital GP VI LLC — Director
Code (U): 3,099,265EDGAR
2025-08-084Jerel Davis — DirectorCode (U): 274,990 · Code (U): 2,726,322 · Code (U): 207,486 · Code (U): 90,888 · Code (U): 82,006EDGAR
2025-08-084Gupta Rishi — DirectorCode (U): 3,099,265EDGAR
2024-07-024Rajangam Kanya — DirectorGrant/award (A): 12,770 (derivative) @ $0EDGAR
2024-07-024Jerel Davis — Director, 10% ownerGrant/award (A): 12,770 (derivative) @ $0EDGAR
2024-07-024Gould Robert J — DirectorGrant/award (A): 12,770 (derivative) @ $0EDGAR
2024-07-024Waddill William D. — DirectorGrant/award (A): 12,770 (derivative) @ $0EDGAR
2024-07-024Gupta Rishi — Director, 10% ownerGrant/award (A): 12,770 (derivative) @ $0EDGAR
2024-04-164Waddill William D. — DirectorGrant/award (A): 25,540 (derivative) @ $0EDGAR
2024-01-114FMR LLCHoldings only — no transactions reportedEDGAR
2023-10-174Ramanan Venkat — Chief Financial OfficerGrant/award (A): 46,606 (derivative) @ $0EDGAR
2023-10-174Rajangam Kanya — DirectorGrant/award (A): 8,012 (derivative) @ $0EDGAR
2023-10-174Campisi Peter Joseph Jr. — Chief Legal OfficerGrant/award (A): 44,377 (derivative) @ $0EDGAR
2023-10-174Burgess Michael F. — Interim Chief Medical Officer, DirectorGrant/award (A): 11,464 (derivative) @ $0EDGAR
2023-10-174Azmat Saryah — Chief Business OfficerGrant/award (A): 56,637 (derivative) @ $0EDGAR
2023-10-174Farah Sammy J. — President & CEO, DirectorGrant/award (A): 155,321 (derivative) @ $0EDGAR
2023-10-174Jerel Davis — Director, 10% ownerGrant/award (A): 25,540 (derivative) @ $0EDGAR
2023-10-174ABBOT STEWART — Chief Scientific OfficerGrant/award (A): 45,542 (derivative) @ $0EDGAR
2023-10-174Gupta Rishi — Director, 10% ownerGrant/award (A): 25,540 (derivative) @ $0EDGAR
2023-07-274FMR LLC — 10% ownerConversion (C): 91,663 · Conversion (C): 106,496 · Conversion (C): 150,809 · Conversion (C): 483,684 · Conversion (C): 296,396 · Conversion (C): 4,939 · +6 moreEDGAR
2023-07-274Jerel Davis — Director, 10% ownerConversion (C): 2,528,864 · Conversion (C): 192,458 · Conversion (C): 84,313 · Conversion (C): 76,067 · Conversion (C): 274,990 · Purchase (P): 197,458 @ $12 · +20 moreEDGAR
2023-07-274Versant Ventures V, LLC — 10% owner
Versant Venture Capital V, L.P. — 10% owner
Versant Ophthalmic Affiliates I, L.P. — 10% owner
Versant Affiliates Fund V, L.P. — 10% owner
Versant Ventures V GP-GP (Canada), Inc. — 10% owner
Versant Ventures V (Canada), L.P. — 10% owner
Versant Venture Capital V (Canada), LP — 10% owner
Versant Vantage II GP-GP, LLC — 10% owner
Versant Vantage II GP, L.P. — 10% owner
Versant Vantage II, L.P. — 10% owner
Conversion (C): 2,528,864 · Conversion (C): 192,458 · Conversion (C): 84,313 · Conversion (C): 76,067 · Conversion (C): 274,990 · Purchase (P): 197,458 @ $12 · +20 moreEDGAR
2023-07-244Gupta Rishi — Director, 10% ownerConversion (C): 2,682,599 · Purchase (P): 416,666 @ $12 · Conversion (C): 937,372 (derivative) · Conversion (C): 1,249,829 (derivative) · Conversion (C): 266,240 (derivative) · Conversion (C): 229,158 (derivative)EDGAR
2023-07-244ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VI LLC — Director, 10% owner
Conversion (C): 2,682,599 · Purchase (P): 416,666 @ $12 · Conversion (C): 937,372 (derivative) · Conversion (C): 1,249,829 (derivative) · Conversion (C): 266,240 (derivative) · Conversion (C): 229,158 (derivative)EDGAR

Recent 8-K events — Turnstone Biologics Corp.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2025-08-118-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2025-07-178-K/A5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2025-07-018-K/A9.01 — Financial Statements and ExhibitsEDGAR
2025-06-278-K1.01 — Entry into a Material Definitive Agreement
1.02 — Termination of a Material Definitive Agreement
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-05-098-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-04-018-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2025-03-318-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-02-048-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-11-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-10-118-K?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TSBX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs